Literature DB >> 11520784

Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.

R Chian1, S Young, A Danilkovitch-Miagkova, L Rönnstrand, E Leonard, P Ferrao, L Ashman, D Linnekin.   

Abstract

Stem cell factor (SCF) binds the receptor tyrosine kinase c-Kit and is critical for normal hematopoiesis. Substitution of valine for aspartic acid 816 (D816V) constitutively actives human c-Kit, and this mutation is found in patients with mastocytosis, leukemia, and germ cell tumors. Immortalized murine progenitor cells (MIHCs) transduced with wild-type c-Kit proliferate in response to SCF, whereas cells expressing D816V c-Kit (MIHC-D816V) are factor-independent and tumorigenic. However, the mechanisms mediating transformation by D816V c-Kit are unknown. The objective of this study was to identify signaling components that contribute to D816V c-Kit-mediated transformation. SCF stimulates association of p85PI3K with phosphorylated tyrosine 721 of wild-type c-Kit. Phosphatidylinositol 3 kinase (PI3K) subsequently contributes to the activation of Akt and Jnks. In contrast, these studies demonstrated that the D816V c-Kit mutant was constitutively associated with phosphorylated p85PI3K, and, downstream of PI3K, Jnk 1 and Jnk 2 were activated but Akt was not. Interestingly, Erks 1 and 2 were not constitutively activated by D816V c-Kit. Thus, D816V c-Kit maintains the activity of PI3K but not of all signaling pathways activated by wild-type c-Kit. Further, all pathways downstream of PI3K are not constitutively active in MIHC-D816V cells. Studies with a PI3K inhibitor and D816V/Y721F c-Kit, a mutant incapable of recruiting PI3K, indicate that constitutive activation of PI3K through direct recruitment by D816V c-Kit plays a role in factor-independent growth of MIHC and is critical for tumorigenicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520784     DOI: 10.1182/blood.v98.5.1365

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.

Authors:  Jianmin Sun; Malin Pedersen; Lars Rönnstrand
Journal:  J Biol Chem       Date:  2009-03-05       Impact factor: 5.157

2.  Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

Authors:  Noria Harir; Cédric Boudot; Katrin Friedbichler; Karoline Sonneck; Rudin Kondo; Séverine Martin-Lannerée; Lukas Kenner; Marc Kerenyi; Saliha Yahiaoui; Valérie Gouilleux-Gruart; Jean Gondry; Laurence Bénit; Isabelle Dusanter-Fourt; Kaïss Lassoued; Peter Valent; Richard Moriggl; Fabrice Gouilleux
Journal:  Blood       Date:  2008-06-25       Impact factor: 22.113

3.  Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Authors:  Gregor Hoermann; Sabine Cerny-Reiterer; Andrea Perné; Miriam Klauser; Konrad Hoetzenecker; Katharina Klein; Leonhard Müllauer; Marion Gröger; Sebastian M B Nijman; Walter Klepetko; Peter Valent; Matthias Mayerhofer
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

Review 4.  Neoplasms associated with germline and somatic NF1 gene mutations.

Authors:  Sachin Patil; Ronald S Chamberlain
Journal:  Oncologist       Date:  2012-01-12

5.  PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability.

Authors:  Yasuko Furumoto; Nicolas Charles; Ana Olivera; Wai Hang Leung; Sandra Dillahunt; Jennifer L Sargent; Kevin Tinsley; Sandra Odom; Eric Scott; Todd M Wilson; Kamran Ghoreschi; Manfred Kneilling; Mei Chen; David M Lee; Silvia Bolland; Juan Rivera
Journal:  Blood       Date:  2011-09-16       Impact factor: 22.113

6.  Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.

Authors:  Thomas Kamenz; Karel Caca; Thilo Blüthner; Andrea Tannapfel; Joachim Mössner; Marcus Wiedmann
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

7.  The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Authors:  S Agarwal; J U Kazi; S Mohlin; S Påhlman; L Rönnstrand
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

8.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Rong Zeng; Yaddanapudi Ravindranath; Gary Dahl; Norman J Lacayo; David Becton; Myron Chang; Howard J Weinstein; Betsy Hirsch; Susana C Raimondi; Nyla A Heerema; William G Woods; Beverly J Lange; Craig Hurwitz; Robert J Arceci; Jerald P Radich; Irwin D Bernstein; Michael C Heinrich; Soheil Meshinchi
Journal:  Blood       Date:  2010-01-07       Impact factor: 22.113

9.  Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.

Authors:  Veerendra Munugalavadla; Emily C Sims; Jovencio Borneo; Rebecca J Chan; Reuben Kapur
Journal:  Blood       Date:  2007-05-04       Impact factor: 22.113

Review 10.  Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.

Authors:  Glenn Cruse; Dean D Metcalfe; Ana Olivera
Journal:  Immunol Allergy Clin North Am       Date:  2014-03-12       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.